Materialise, the Additive Manufacturing solutions company headquartered in Leuven, Belgium, has invested in Engimplan Implants Engineering, a manufacturer of orthopaedic and cranio-maxillofacial (CMF) implants and instruments based in Rio Claro, Brazil, to accelerate the introduction of additively manufactured, personalised implants and instruments into the Brazilian market.
According to Materialise, it has signed an agreement to acquire a 75% stake in Engimplan through a combined acquisition of existing and new shares via its Brazilian subsidiary Engimplan Holding Ltda. As part of the transaction, Materialise will gain access to Engimplan’s local production facility, expand the company’s portfolio with its experience, and enter its existing partner and distribution network in Brazil. The closing of the transaction is expected to take place in August.
“Surgical planning and 3D printing are increasingly adopted by orthopaedic and CMF surgeons, as they understand the positive impact of personalised implants and patient-specific solutions on surgical outcomes,” stated Brigitte de Vet, Vice President and General Manager of Materialise Medical. “With this investment, we will expand our medical product and service portfolio, confirming our commitment to strengthen our position and grow our global presence in the medical industry.”
José Tadeu Leme, CEO of Engimplan, commented, “This investment by Materialise sends a strong signal to our customers and the industry that we remain committed to developing our innovative solutions that improve the lives of many people, and that we have the confidence and support of a pioneer and global leader in 3D printing. Together, we can introduce new levels of innovation in the development of personalised implants in Brazil.”